Clinical trials: Intravenous Infusions
Healthy Volunteers
A Phase 1 Study to Evaluate Pharmacokinetics, Safety and Tolerability of ZL-1503 in Healthy Volunteers
This is a phase 1, single dose, randomized, open-label, parallel-group study to evaluate the pharmacokinetics (PK), safety, tolerability and immunogenicity of ZL-1503 and to explore its PD biomarkers following a single…
- Trial name
- NCT07658482
- Testing
- ZL-1503
- Where
- New Zealand
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Healthy
Safety, Tolerability, Pharmacokinetic Characteristics of hzVSF-v13 in Healthy Male Volunteers
To investigate the safety/tolerability and pharmacokinetic characteristics after single intravenous (IV) administration of hzVSF-v13 (humanized Virus Suppressing Factor-variant 13) in healthy male volunteers
- Trial name
- NCT03653208
- Testing
- hzVSF-v13
- Where
- South Korea
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- ImmuneMed, Inc.
Healthy
Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po
This Phase IV study is intended to compare intragastric acid suppression of oral esomeprazole (NEXIUM ® Delayed-Release Capsules) with that of oral pantoprazole (PROTONIX ® Delayed Release Tablets ), in subjects who continue to…
- Trial name
- NCT00206050
- Testing
- Esomeprazole, pantoprazole
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Epilepsy, Partial Onset Seizures
An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures
To evaluate the safety of Levetiracetam IV 15-minute infusion administered every 12 hours as adjunctive treatment in subjects with Partial Onset Seizures after switching from the equivalent Levetiracetam oral dose.
- Trial name
- NCT01407523
- Testing
- Levetiracetam
- Where
- 4 sites in Japan
- Volunteers
- 16 people
- Sponsor
- UCB Japan Co. Ltd.
Human Volunteers
An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese
The part A of N01362 is to evaluate the bioequivalence of Levetiracetam (LEV) 1500 mg intravenous (iv) infusion when compared to tablet oral administration in Chinese healthy volunteers.
- Trial name
- NCT01618903
- Testing
- Levetiracetam
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- UCB Pharma
Cancer
Safety Study of MBP-426 (Liposomal Oxaliplatin Suspension for Injection) to Treat Advanced or Metastatic Solid Tumors
The purpose of this study is to determine whether MBP-426 (liposomal oxaliplatin suspension for injection) is safe and effective in the treatment of advanced or metastatic solid tumors.
- Trial name
- NCT00355888
- Testing
- MBP-426
- Where
- 2 sites in United States
- Volunteers
- 39 people
- Sponsor
- Mebiopharm Co., Ltd
Healthy Volunteers
A Study to Assess Safety, Tolerability, Pharmacokinetics (PK), Immunogenicity, and Pharmacodynamics (PD) of Intravenous Infusions of E2814 in Healthy Participants
The primary objective of this study is to evaluate the safety and tolerability of single and multiple intravenous infusions of E2814 in healthy adult participants.
- Trial name
- NCT04231513
- Testing
- E2814
- Where
- 2 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Rheumatoid Arthritis
ALX-0061 Phase I Bioavailability Study in Healthy Volunteers
The overall aims of the study are: To assess the bioavailability of single doses of ALX-0061, administered s.c. at three dose levels, using 2 corresponding single i.v. dose levels as reference.
- Trial name
- NCT02101073
- Testing
- ALX-0061
- Where
- Netherlands
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Ablynx, a Sanofi company
Myelogenous Leukemia, Acute
A Study of RO5429083 Alone or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia
This multi-center, open-label study will evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of RO5429083 alone and in combination with cytarabine in patients with acute myelogenous leukemia.
- Trial name
- NCT01641250
- Testing
- RO5429083, cytarabine
- Where
- 8 sites in France, Germany and 1 more
- Volunteers
- 44 people
- Sponsor
- Hoffmann-La Roche
Pain, Acute Pain
A Phase 1, Randomized, Placebo-Controlled Safety and Tolerability Study Of Intravenous SBS-1000 in Healthy Adults
This study will be a single-center, double-blind, randomized placebo-controlled, adaptive, single ascending dose study.
- Trial name
- NCT05721287
- Testing
- SBS-1000
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Sparian Biosciences, Inc
Infection, Intra-abdominal
Dragon Study (the Safety and Efficacy for Treatment of Patients With Complicated Intra Abdominal Infections)
The purpose of this study is to assess the safety and efficacy of intravenous administration Moxifloxacin (BAY 12-8039) compared to intravenous ceftriaxone and metronidazole for the treatment of patients with complicated intra…
- Trial name
- DRAGON (NCT00769171)
- Testing
- Avelox (Moxifloxacin, BAY12-8039), Ceftriaxone + Metronidazole
- Where
- 25 sites in China, Hong Kong and 4 more
- Volunteers
- 364 people
- Sponsor
- Bayer
Healthy Participants, Obesity
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or…
- Trial name
- NCT07511205
- Testing
- AZD1043
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Chronic Renal Failure
rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics
The study is a single center and open test, and the dose of successive incremental method was taken. In order to determine the tolerance and safety after a single intravenous injection of different doses of rESP in healthy…
- Trial name
- NCT02356419
- Testing
- Recombinant erythropoietin stimulating protein
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Stroke, Ischemia
A Safety and Tolerability Study of 42037788 (Referred to as CNTO 0007) Compared With Placebo in Patients Who Have Experienced Ischemic Cerebral Infarction (Also Known as Stroke)
The purpose of this study is to evaluate the safety and tolerability of 42037788 (CNTO 0007) in patients who have suffered a stroke.
- Conditions
- Stroke, Ischemia, Infarction
- Trial name
- NCT01273467
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- Janssen Research & Development, LLC
Pulmonary Disease, Chronic Obstructive
A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719
This will be a two-period, open-label study conducted at a single site. Six healthy male subjects will participate in the study to ensure at least four fully evaluable subjects.
- Trial name
- NCT01362257
- Testing
- Treatment Period 1 - IV dose of GSK573719, Treatment Period 2 - Oral dose of GSK573719
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Cancer
Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors
This is a Phase I, dose escalation study of EM-1421 administered by intravenous infusion (IV) for five consecutive days every 28 days to patients with solid tumors refractory to current therapies.
- Trial name
- NCT00259818
- Testing
- EM-1421
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Erimos Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells
This phase II study is a randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of UMC119-06-05 compared to placebo in treating subjects with moderate to severe COPD.
- Trial name
- NCT06491043
- Testing
- UMC119-06-05
- Where
- 2 sites in Taiwan
- Volunteers
- 90 people
- Sponsor
- Meribank Biotech Co., Ltd.
Lung Injury, Acute
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of an Intravenous Infusion of GW328267X in Healthy Volunteers
This study is a single dose evaluation using an open label dose escalating design. Cohort1 will consist of 3 healthy male volunteers.
- Trial name
- NCT01640990
- Testing
- Saline, GW328267X (total dose of 12mcg), GW328267X (total dose of 40mcg)
- Where
- United Kingdom
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Advanced Cancer
A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer
This study will evaluate the safety, pharmacokinetics (PK), and pharmacodynamic effects of a novel anti-cancer drug, EPC2407, administered to patients with advanced cancer which have not responded to or have recurred following…
- Trial name
- NCT00423410
- Testing
- EPC2407 (crinobulin)
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- EpiCept Corporation
Advanced Solid Tumor, Metastatic Solid Tumor
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in…
- Trial name
- NCT06108050
- Testing
- JZP898, Pembrolizumab
- Where
- 10 sites in United States
- Volunteers
- 177 people
- Sponsor
- Jazz Pharmaceuticals